Cutia Therapeutics (2487.HK)
HKD 6.95
(0.14%)
HKD 6.95
(0.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.91 Billion CNY | -269.41% |
| 2022 | -535.18 Million CNY | -70.74% |
| 2021 | -309.22 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -102.6 Million CNY | 0.0% |
| 2024 Q1 | -102.6 Million CNY | 33.68% |
| 2023 Q4 | -154.7 Million CNY | 0.0% |
| 2023 Q3 | -154.7 Million CNY | -55.17% |
| 2023 FY | - CNY | -269.41% |
| 2023 Q2 | -99.69 Million CNY | 0.0% |
| 2023 Q1 | -99.69 Million CNY | -15.34% |
| 2022 FY | - CNY | -70.74% |
| 2022 Q4 | -86.43 Million CNY | 0.0% |
| 2022 Q3 | -86.43 Million CNY | 0.0% |
| 2021 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 2200.968% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 493.758% |